Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer

Table 2

The clinicopathological characteristics of patients in different risk groups.

Clinicopathological variables	Patients ()	Risk group		value
		High (82)	Low (82)
Alcohol history				0.15
Present	96	53	43
Absent	68	29	39
Diabetes				0.026
Present	48	31	17
Absent	116	51	65
Tumor size (cm)				0.43
<4	86	40	46
≧4	78	42	36
Lymphnode metastasis				0.38
Present	118	62	56
Absent	46	20	26
Distant metastasis				1
Present	92	46	46
Absent	72	36	36
TNM stage				0.00046
Advanced (IIA, III, & IV)	119	70	49
Early (I & IIA)	45	12	33
Differentiation				0.00055
Poor	47	34	13
Well	117	48	69